ABcann amended and extended the research contract in place with the University of Guelph. The ongoing research is focused on the controlled environment production of medicinal cannabis and has become a contributing factor to increasing yields and a higher quality, pesticide free standardized product. ABcann welcomed two new additional advisors in Prof. Raphael Mechoulam and W. Brett Wilson. The Company also appointed Dr. Michael Shannon as its chief medical consultant. Subsequent to June 30, 2017: ABcann was included in the Horizons Medical Marijuana Life Sciences ETF. The ETF offers investors direct exposure to a basket of North American publicly listed companies that meet minimum asset and liquidity thresholds. Additional listings on both the OTCQB Marketplace (ABCCF) and FSE, the Frankfurt Stock Exchange (23Q) were obtained. The Company completed a private placement financing of common shares to CBW at a price of $2.25 per share for proceeds of $15m. The Company received approximately $7.5m in additional proceeds from the exercises of nearly 12m warrants issued in connection with 2014 and 2015 private placements. These warrants were to expire on September 9, 2017. About ABcann Global Corporation (TSX.V: ABCN) : ABcann was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann’s flagship facility in Napanee, Ontario utilizes proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less- controlled, larger rooms and greenhouse-type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product. ABcann is expanding capacity in its current facility to approximately 30,000 sq ft and concurrently undertaking its expansion into a new 150,000 sq ft facility in Napanee. ABcann is pursuing opportunities in Germany, Australia and other jurisdictions as well as exploring the development of multiple delivery vehicles.